Camptothecin and topotecan inhibit adipocyte differentiation by inducing degradation of PPARγ

Jung Hoon Kim, Manhyung Jeong, Sang Sik Lee, Jaewhan Song

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Camptothecin is an anti-cancer drug extracted from Camptotheca acuminata, a tree native to mainland China. Phase III clinical trials for camptothecin have been completed, and it is now used as a chemotherapeutic reagent. We identified a novel function of camptothecin that affects adipocyte differentiation. Following treatment with camptothecin, endogenous or overexpressed PPARγ becomes destabilized; this was prevented in the presence of MG132, a proteasome inhibitor. Our findings suggest that camptothecin is able to induce proteasome-dependent degradation of PPARγ. The ubiquitylation of PPARγ increased in the presence of camptothecin. Adipogenic differentiation of 3T3-L1 cells was prevented by campothecin and topotecan, but not by irinotecan, confirming our initial findings. Our results suggest a possible role for camptothecin analogs in the regulation of PPARγ.

Original languageEnglish
Pages (from-to)1122-1128
Number of pages7
JournalBiochemical and Biophysical Research Communications
Volume463
Issue number4
DOIs
Publication statusPublished - 2015 Jul 13

Fingerprint

Topotecan
Camptothecin
Peroxisome Proliferator-Activated Receptors
Adipocytes
Degradation
irinotecan
Camptotheca
3T3-L1 Cells
Phase III Clinical Trials
Proteasome Inhibitors
Ubiquitination
Proteasome Endopeptidase Complex
China
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

@article{598a5b6e72c04dc9bb18628b6b9377d3,
title = "Camptothecin and topotecan inhibit adipocyte differentiation by inducing degradation of PPARγ",
abstract = "Camptothecin is an anti-cancer drug extracted from Camptotheca acuminata, a tree native to mainland China. Phase III clinical trials for camptothecin have been completed, and it is now used as a chemotherapeutic reagent. We identified a novel function of camptothecin that affects adipocyte differentiation. Following treatment with camptothecin, endogenous or overexpressed PPARγ becomes destabilized; this was prevented in the presence of MG132, a proteasome inhibitor. Our findings suggest that camptothecin is able to induce proteasome-dependent degradation of PPARγ. The ubiquitylation of PPARγ increased in the presence of camptothecin. Adipogenic differentiation of 3T3-L1 cells was prevented by campothecin and topotecan, but not by irinotecan, confirming our initial findings. Our results suggest a possible role for camptothecin analogs in the regulation of PPARγ.",
author = "Kim, {Jung Hoon} and Manhyung Jeong and Lee, {Sang Sik} and Jaewhan Song",
year = "2015",
month = "7",
day = "13",
doi = "10.1016/j.bbrc.2015.06.069",
language = "English",
volume = "463",
pages = "1122--1128",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "4",

}

Camptothecin and topotecan inhibit adipocyte differentiation by inducing degradation of PPARγ. / Kim, Jung Hoon; Jeong, Manhyung; Lee, Sang Sik; Song, Jaewhan.

In: Biochemical and Biophysical Research Communications, Vol. 463, No. 4, 13.07.2015, p. 1122-1128.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Camptothecin and topotecan inhibit adipocyte differentiation by inducing degradation of PPARγ

AU - Kim, Jung Hoon

AU - Jeong, Manhyung

AU - Lee, Sang Sik

AU - Song, Jaewhan

PY - 2015/7/13

Y1 - 2015/7/13

N2 - Camptothecin is an anti-cancer drug extracted from Camptotheca acuminata, a tree native to mainland China. Phase III clinical trials for camptothecin have been completed, and it is now used as a chemotherapeutic reagent. We identified a novel function of camptothecin that affects adipocyte differentiation. Following treatment with camptothecin, endogenous or overexpressed PPARγ becomes destabilized; this was prevented in the presence of MG132, a proteasome inhibitor. Our findings suggest that camptothecin is able to induce proteasome-dependent degradation of PPARγ. The ubiquitylation of PPARγ increased in the presence of camptothecin. Adipogenic differentiation of 3T3-L1 cells was prevented by campothecin and topotecan, but not by irinotecan, confirming our initial findings. Our results suggest a possible role for camptothecin analogs in the regulation of PPARγ.

AB - Camptothecin is an anti-cancer drug extracted from Camptotheca acuminata, a tree native to mainland China. Phase III clinical trials for camptothecin have been completed, and it is now used as a chemotherapeutic reagent. We identified a novel function of camptothecin that affects adipocyte differentiation. Following treatment with camptothecin, endogenous or overexpressed PPARγ becomes destabilized; this was prevented in the presence of MG132, a proteasome inhibitor. Our findings suggest that camptothecin is able to induce proteasome-dependent degradation of PPARγ. The ubiquitylation of PPARγ increased in the presence of camptothecin. Adipogenic differentiation of 3T3-L1 cells was prevented by campothecin and topotecan, but not by irinotecan, confirming our initial findings. Our results suggest a possible role for camptothecin analogs in the regulation of PPARγ.

UR - http://www.scopus.com/inward/record.url?scp=84936985919&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84936985919&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2015.06.069

DO - 10.1016/j.bbrc.2015.06.069

M3 - Article

C2 - 26079886

AN - SCOPUS:84936985919

VL - 463

SP - 1122

EP - 1128

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 4

ER -